January 10th 2024
The oral TRT study plans to enroll 20 male patients aged 18 to 49 years who meet the American Urological Association’s criteria for hypogonadism and who have not previously used TRT.
September 28th 2023
Expert Perspectives on Emerging CDK4/6 Inhibitor Strategies in Advanced Prostate Cancer Management Settings
View More
New York GU 17th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies
March 8-9, 2024
Register Now!
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Will Emerging Data Inform Treatment Planning for Patients With Prostate Cancer in the Community?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Oral testosterone agents mark important paradigm shift
June 12th 2020"The rigorous study and promising clinical availability of oral therapy for testosterone deficiency are flash points in the current era, in which the utility of testosterone therapy is under critical review," writes Arthur L. Burnett II, MD, MBA.
Exceeding exercise guidelines may reduce likelihood of low T in men
May 27th 2020Men whose activity exceeded guideline-based exercise levels experienced a decreased likelihood of lower serum testosterone, according to study results presented at the American Urological Association 2020 Virtual Experience.
Penile traction device shows benefit in men post-radical prostatectomy
March 25th 2020Interim results from a clinical trial of a next-generation penile traction therapy device were encouraging and demonstrated statistically significant increases in penile length and a smaller reduction in erectile function among post-prostatectomy men who were treated with the device, known as RestoreX, according to PathRight Medical.
Prednisone may improve total motile count post vasectomy reversal
February 28th 2020A course of treatment with prednisone may offer improvement in mean total motile count for men who undergo vasectomy reversal and subsequently have partial or complete anastomotic obstruction, according to a recent study.
PAE safe, durable for retention, hematuria in non-index BPH patients
January 28th 2020Prostatic artery embolization offers a safe and durably effective treatment for urinary retention and gross hematuria in challenging non-index BPH patients, according to the results of a retrospective study published in Urology (Nov. 14, 2019 [Epub ahead of print]).
Protocol cuts narcotic use in IPP patients
January 15th 2020Researchers studying a novel multimodal analgesia protocol at multiple institutions in the U.S. for patients having penile implant surgery found narcotic prescriptions before, during, and in the post-surgery recovery period fell from as high as 50 to 60 narcotic pills to 10 to 15 pills.
Guideline adherence raises infection risk in diabetic penile prosthesis patients
December 3rd 2019Guideline-directed care often leads to better outcomes, but that’s not the case with the AUA’s antibiotic prophylaxis guidelines for diabetic patients undergoing primary penile prosthesis implantation. Authors of an ongoing study have found that adhering to the antibiotic prophylaxis guidelines results in a five-fold increased infection risk among diabetic penile prothesis patients, greatly increasing their risk for explantation.
New data point to statins’ potential for reducing prostate growth
November 27th 2019Results from analyses of data collected in the randomized, placebo-controlled Reduction by Dutasteride of prostate Cancer Events (REDUCE) trial point to a potential role for statins in attenuating age-related prostate enlargement.
Data from 18-year study support HoLEP’s efficacy
November 19th 2019Findings from an analysis of data collected prospectively over an 18-year period provide further evidence supporting guidelines that recommend holmium laser enucleation of the prostate as the size-independent gold standard for surgical management of BPH, say urologists from McGill University, Montreal.
Nomograms predict erectile function recovery
November 15th 2019A set of evidence-based nomograms for predicting recovery of erectile function after radical prostatectomy is now available, and the developers hope that surgeons will use these tools to provide prostate cancer patients with a more accurate personalized estimate of their sexual function outcome.
Study: ED questionnaire lacks crucial questions
November 6th 2019A patient-reported outcomes survey that is widely used to determine whether men are experiencing erectile dysfunction (ED) fails to ask three critical questions that could uncover whether men truly have ED and the extent to which they face challenges, researchers say.
New data point to statins’ potential for reducing prostate growth
November 1st 2019Results from analyses of data collected in the randomized, placebo-controlled Reduction by Dutasteride of prostate Cancer Events (REDUCE) trial point to a potential role for statins in attenuating age-related prostate enlargement.